Xartemis is developed by Lotus Clinical Research, LLC.

What development phase is Xartemis in?

Xartemis is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Xartemis

Lotus Clinical Research, LLC · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Xartemis
Sponsor	Lotus Clinical Research, LLC
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Pharmacokinetics (PK) and Safety Study of XARTEMIS® XR in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain (PHASE4)
An Open Label, Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP( Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain. (PHASE4)
Open-Label Study of Oxycodone/APAP to Treat Post-Operative Pain Following Arthroscopic Knee Surgery (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Xartemis CI brief — competitive landscape report
Xartemis updates RSS · CI watch RSS
Lotus Clinical Research, LLC portfolio CI